Cannara Biotech Inc. Reports Preliminary Results Ahead of Third Quarter 2021

Preliminary results from first commercial quarter in market show successful market launch in Quebec

MONTREAL, June 28, 2021 /CNW Telbec/ – Cannara Biotech Inc. (“Cannara” or the “Company”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), is pleased to announce preliminary unaudited revenue results for the three-month period ended May 31, 2021, marking the retail debut for the Company.

“Our market launch results reaffirm that our brand strategy is working and will deliver long-term value for our shareholders,” said Zohar Krivorot, President & Chief Executive Officer of Cannara. “Cannara intimately understands the quality and pricing that today’s modern consumer deserves, and we look forward to expanding our market reach with added capacity from the acquisition of our Valleyfield facility.”

“We could not be more pleased with our preliminary results which validates our capabilities and foresight  in responding to consumer demand,” said Nicholas Sosiak, Chief Financial Officer of Cannara. “As a part of our strategy to expand our market reach, our acquisition of the Valleyfield facility was driven by our anticipation of the tremendous growth in revenue over this past quarter.”

Preliminary Third Quarter 2021 Highlights

• The Company expects total revenue, net of excise tax, for the third quarter ended May 2021 to be approximately $7.1 million, representing a $5.1 million increase compared to the second quarter of 2021.
• Cannabis revenue, net of excise tax, from products destined for retail is expected to be in the range of $3.2 to $3.4 million for the quarter.
• Cannabis revenue from wholesale supply agreements is expected to be in the range of $2.8 to $2.9 million up from $1.1 million the previous quarter.
• Lease revenue is expected to be approximately $0.8 million for the quarter.

Results were driven by strong consumer response to premium-quality cannabis launched at disruptive pricing in March 2021, as well as increased demand for product through our wholesale supply agreements.  The Company initially introduced 7 unique SKUs under three flagship brands; Tribal, Nugz, and Orchid CBD.  With the acquisition of its Valleyfield facility, output capacity has the potential of  reaching 125,000kg per annum. This will allow the Company to introduce additional SKUs and accelerate its genetic rotation mix.

Outlook and Full Q3 2021 Results

Looking ahead, Cannara expects to begin work on its Valleyfield facility to further increase the supply of products to meet current demand in Quebec.The Company recently launched new cannabis genetics, including its well-received Cuban Linx and Do-Si-Dos strains in June 2021, and intends on releasing additional strains as well as a new line of hash products.

Cannara expects to announce its third quarter financial and operating results in full by July 30, 2021.

Cannara’s CFO, Nicholas Sosiak, will be a guest speaker at the 2021 KCSA Cannabis Virtual Investor Conference on June 30 at 11:30 a.m. ET and will be available to answer investor and analysts’ questions. To register for the conference, please visit the event’s KCSA’s registration page.

About Cannara Biotech Inc.

Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB) is a vertically integrated producer of premium–grade cannabis and cannabis–derivative products for the Quebec and Canadian markets. Cannara owns two mega Quebec–based facilities spanning over 1,650,000 sq. ft., providing the Company with 125,000kg of potential annualized cultivation output. Leveraging Quebec’s low electricity costs, Cannara’s facilities produce craft cultivated premium–grade cannabis products at an affordable price. For more information, please visit cannara.ca.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding “Forward–Looking” Information

This information release contains certain forward–looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward–looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward–looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward–looking statements, whether as a result of new information, future events or otherwise.

SOURCE Cannara Biotech Inc.

For further information: Nicholas Sosiak, CPA, CA, Chief Financial Officer, [email protected]; Zohar Krivorot, President & Chief Executive Officer, [email protected]

Related Links

http://cannara.ca/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.